Kezar Life Sciences (NASDAQ: KZR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.260 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kezar Life Sciences (NASDAQ: KZR) through any online brokerage.
Other companies in Kezar Life Sciences’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Centessa Pharmaceuticals (NASDAQ:CNTA), Altimmune (NASDAQ:ALT) and Immatics (NASDAQ:IMTX).
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by Wells Fargo on Tuesday, June 28, 2022. The analyst firm set a price target for 17.00 expecting KZR to rise to within 12 months (a possible 82.99% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Kezar Life Sciences (NASDAQ: KZR) is $9.29 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Kezar Life Sciences.
Kezar Life Sciences’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Kezar Life Sciences.
Kezar Life Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.